Tesamorelin is a stabilised synthetic analogue of GHRH, the growth hormone-releasing hormone. Its sequence is derived from GHRH(1–44), with a modification designed to reduce its degradation. This characteristic explains its use as a tool for studying the GHRH receptor and the downstream signalling pathway. Optima Labs’ reference product is packaged for laboratory use; it is important to distinguish between the commercial concentration and the conditions of use in a scientific article.

Search mechanism

The GHRH receptor belongs to the family of G protein-coupled receptors. Its activation is associated with an increase in cyclic AMP and signalling events which, in the physiological context, are involved in the regulation of the GH–IGF–1 axis. An in vitro model must specify whether the receptor is endogenous or overexpressed, the level of expression, the response time and the marker being measured. The response of a single-cell construct does not automatically replicate the entire endocrine axis.

Areas of research

Research focuses on GHRH receptor pharmacology, analogue stability, cyclic AMP-dependent signalling and, in regulated clinical settings, certain metabolic parameters. Trials in people with HIV who have abdominal fat accumulation constitute a specific clinical dataset. They should not be generalised to other populations nor turned into a laboratory protocol. For a molecular comparison, include native GHRH, tesamorelin and a vehicle control under justified equimolar conditions.

Findings reported in the literature

Several randomised trials have investigated tesamorelin in specific populations. A trial published in 2010 followed participants with HIV who had abdominal fat accumulation; a multicentre study published in 2019 assessed hepatic fat and histology in a subgroup with steatosis. These results are derived from clinical protocols and a controlled substance. They document the molecule, but do not establish any clinical purpose for the investigational product being marketed here.

Further information

The characterisation of a long peptide requires the integration of chromatography, identity confirmation and content analysis. Potential degradation or aggregation depends on preparation and storage conditions. Retain batch data, the chromatogram, the method and the preparation parameters together with the experimental record. This reference is intended solely for in vitro and analytical research. It must not be used in humans or animals.

Peptides de recherche

CJC-1295 + Ipamoréline (sans DAC)

Tésamoréline